Alnylam presents positive preliminary data for ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ: ALNY) has presented positive preliminary results at a medical conference in Japan from its Phase 1 clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis  (ATTR). Data from the study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels [...]

Tekmira partner starts human trials of ALN-TTR01

Alnylam Pharmaceuticals (NASDAQ:ALNY), one of Tekmira Pharmaceuticals‘ (TSX:TKM) partners, has initiated dosing in a Phase 1 clinical trial of its ALN-TTR01 product candidate in patients with transthyretin-mediated amyloidosis (ATTR), a disease that results in damage to the peripheral nerves and heart. ALN-TTR01 is a RNA-interference therapeutic that uses Tekmira’s lipid nanoparticle delivery technology, SNALP (stable [...]